[HTML][HTML] Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease
F Åberg, CD Byrne, CJ Pirola, V Männistö… - Journal of …, 2023 - Elsevier
Alcohol use and metabolic syndrome are highly prevalent in the population and frequently
co-exist. Both are implicated in a large range of health problems, including chronic liver …
co-exist. Both are implicated in a large range of health problems, including chronic liver …
Liver cirrhosis
Cirrhosis is widely prevalent worldwide and can be a consequence of different causes, such
as obesity, non-alcoholic fatty liver disease, high alcohol consumption, hepatitis B or C …
as obesity, non-alcoholic fatty liver disease, high alcohol consumption, hepatitis B or C …
Noninvasive proteomic biomarkers for alcohol-related liver disease
Alcohol-related liver disease (ALD) is a major cause of liver-related death worldwide, yet
understanding of the three key pathological features of the disease—fibrosis, inflammation …
understanding of the three key pathological features of the disease—fibrosis, inflammation …
Steatotic liver disease
Steatotic liver disease is the overarching term for conditions characterised by abnormal lipid
accumulation in the liver (liver or hepatic steatosis). Steatotic liver disease encompasses …
accumulation in the liver (liver or hepatic steatosis). Steatotic liver disease encompasses …
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study
Background Steatotic liver disease is a new overarching term that includes metabolic
dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol …
dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol …
Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease
Background & Aims Both metabolic dysfunction and alcohol consumption cause steatotic
liver disease (SLD). The distinction between metabolic dysfunction-associated SLD …
liver disease (SLD). The distinction between metabolic dysfunction-associated SLD …
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial
M Israelsen, BS Madsen, N Torp… - The Lancet …, 2023 - thelancet.com
Background Alcohol is the leading cause of liver-related mortality worldwide. The gut–liver
axis is considered a key driver in alcohol-related liver disease. Rifaximin-α improves gut …
axis is considered a key driver in alcohol-related liver disease. Rifaximin-α improves gut …
MetALD: new opportunities to understand the role of alcohol in steatotic liver disease
For many years non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease
(ALD) have been considered as two biologically and clinically distinct conditions. According …
(ALD) have been considered as two biologically and clinically distinct conditions. According …
Global prevalence, incidence, and outcomes of alcohol related liver diseases: a systematic review and meta-analysis
X Niu, L Zhu, Y Xu, M Zhang, Y Hao, L Ma, Y Li… - BMC Public Health, 2023 - Springer
Background Alcohol related liver disease (ARLD) is one of the major chronic liver diseases
worldwide. This review aimed to describe the global prevalence, incidence, and outcomes of …
worldwide. This review aimed to describe the global prevalence, incidence, and outcomes of …
Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes
Objective Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve
metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We …
metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We …